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Clinical PerspectiveWhat Is New?Among survivors of lacunar stroke, persons with high white matter hyperintensity burden are most likely to benefit from intensive blood pressure control to prevent recurrent stroke.White matter hyperintensity burden did not significantly distinguish risk of kidney function decline after intensive blood pressure lowering.What Are the Clinical Implications?White matter hyperintensities may contribute to the assessment of the benefit and harm of intensive blood pressure control after lacunar stroke.

Introduction {#jah33823-sec-0009}
============

The ideal blood pressure (BP) target for prevention of recurrent stroke remains an issue of active discussion. New hypertension guidelines recommend a target systolic BP (SBP) of \<130 mm Hg in this population.[1](#jah33823-bib-0001){ref-type="ref"} The SPS3 (Secondary Prevention of Small Subcortical Strokes) randomized trial demonstrated that BP lowering to \<130 mm Hg, compared with 130 to 149 mm Hg, significantly reduced the risk for intracerebral hemorrhage by 60%, but the 19% reduction in all stroke recurrence failed to reach statistical significance.[2](#jah33823-bib-0002){ref-type="ref"} On the other hand, there is great concern that aggressive BP lowering can result in large decreases in kidney function, measured by estimated glomerular filtration rate (eGFR). Higher rates of kidney function decline and acute kidney injury with intensive BP lowering have been demonstrated in SPS3 as well as in other large, randomized trials of BP lowering for primary cardiovascular disease prevention.[3](#jah33823-bib-0003){ref-type="ref"}, [4](#jah33823-bib-0004){ref-type="ref"}, [5](#jah33823-bib-0005){ref-type="ref"}

The clinical significance of such decreases in kidney function remains an issue of active investigation. Observational data show that decreases in eGFR are strongly associated with higher end‐stage renal disease risk.[6](#jah33823-bib-0006){ref-type="ref"} In a clinical trial setting, even small decreases in eGFR from intensive BP lowering were associated with progression to end‐stage renal disease.[7](#jah33823-bib-0007){ref-type="ref"} On the other hand, previous reports from SPS3 and SPRINT (Systolic Blood Pressure Intervention Trial) showed that decreases in eGFR that are specific to the setting of intensive BP lowering may not portend increased risk for further kidney injury or adverse cardiovascular events, but, rather, they represent a hemodynamic phenomenon.[5](#jah33823-bib-0005){ref-type="ref"}, [8](#jah33823-bib-0008){ref-type="ref"} Many experts remain concerned that associations of even small increases in creatinine after intensive BP lowering with poor renal outcomes raise concern for ongoing ischemic injury.[7](#jah33823-bib-0007){ref-type="ref"}, [9](#jah33823-bib-0009){ref-type="ref"} The best strategy for identifying persons at highest risk for kidney function decline with intensive BP lowering is unknown. It is possible that kidney function decline from intensive BP lowering is a result of impaired small‐vessel autoregulation in the kidney. This would imply that persons with greater severity of small vessel disease may be at higher risk for kidney function decline from intensive BP lowering. On the other hand, given that these patients are likely at higher risk of cardiovascular events, they may also derive the most benefit from intensive BP lowering.[10](#jah33823-bib-0010){ref-type="ref"}

White matter hyperintensities (WMHs) are thought to be markers of small vessel disease in the brain.[11](#jah33823-bib-0011){ref-type="ref"} WMHs are known to have higher prevalence in the setting of hypertension and advanced age. They have also been associated with increased risk of stroke‐impaired autoregulation of cerebral vasculature.[10](#jah33823-bib-0010){ref-type="ref"}, [12](#jah33823-bib-0012){ref-type="ref"}, [13](#jah33823-bib-0013){ref-type="ref"} Given the anatomical and vasoregulatory similarities between the brain and kidney and the known association between WMHs and chronic kidney disease,[14](#jah33823-bib-0014){ref-type="ref"}, [15](#jah33823-bib-0015){ref-type="ref"} we hypothesized that those with greater burden of WMHs likely have corresponding small‐vessel disease in the kidney. Consequently, they could be at higher risk of rapid decreases in eGFR after intensive BP lowering. To date, such a relationship has not been investigated.

We conducted a secondary analysis of the SPS3 randomized trial to determine whether the presence of WMHs could identify participants at highest risk of kidney function decline from intensive BP lowering. Given that persons with high WMH burden are at higher risk for stroke recurrence, we were also interested in understanding whether these persons may also derive more benefit from intensive BP lowering for secondary prevention of stroke.

Methods {#jah33823-sec-0010}
=======

Study Design {#jah33823-sec-0011}
------------

The SPS3 trial was a 2×2 factorial trial that randomized participants with recent lacunar stroke to evaluate the effect of an intensive BP target of \<130 mm Hg compared with SBP 130 to 149 mm Hg for the prevention of recurrent stroke.[16](#jah33823-bib-0016){ref-type="ref"} Participants were also randomized to an antiplatelet regimen of aspirin and clopidogrel or aspirin and placebo. The BP trial was open label using the PROBE (prospective randomized open blinded end‐point) study design.[17](#jah33823-bib-0017){ref-type="ref"} Details of the trial design have been published.[16](#jah33823-bib-0016){ref-type="ref"} The study is registered on [ClinicalTrials.gov](http://ClinicalTrials.gov) under NCT00059306.

Participants {#jah33823-sec-0012}
------------

The SPS3 trial enrolled 3020 patients with recent lacunar stroke. Patients with eGFR \<40 mL/min/1.73 m^2^ were excluded from enrollment. After randomization to an antiplatelet arm and a BP arm, participants were followed at least once per month until achievement of the assigned target BP, then every 3 months for a mean of 3.7 years. In our cross‐sectional analysis and our analysis of recurrent stroke, we excluded 53 participants. Fifty of these participants had no WMH score; 3 participants had no creatinine measure at baseline, leaving a total of 2967 participants available for analysis. Our longitudinal analysis of kidney outcomes excluded an additional 513 participants missing a serum creatinine measure at 1 year after randomization, leaving 2454 included participants. All participants signed informed consent, and the trial was approved by all appropriate institutional review boards.

Kidney Function {#jah33823-sec-0013}
---------------

We estimated kidney function from serum creatinine measures using the CKD‐EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.[18](#jah33823-bib-0018){ref-type="ref"} Serum creatinine measures were obtained from all SPS3 participants at a prerandomization visit and annual follow‐up visits until the study end date.[16](#jah33823-bib-0016){ref-type="ref"}

Neuroimaging {#jah33823-sec-0014}
------------

Patients underwent magnetic resonance imaging for clinical management when presenting with the index stroke or recurrent stroke. WMHs were evaluated visually on fluid‐attenuated inversion recovery images using the Age‐Related White Matter Changes, or Wahlund, scale by 4 readers unaware of clinical information.[19](#jah33823-bib-0019){ref-type="ref"} This semiquantitative scale rates WMH severity from 0 to 3 in 5 predefined areas of each brain hemisphere for a total possible range of 0 to 30.[20](#jah33823-bib-0020){ref-type="ref"} Inter‐rater agreement among readers was good to excellent on a sample of 40 magnetic resonance imagings: (Cohen\'s kappa=0.64--0.89; 77--89% agreement).

Intervention {#jah33823-sec-0015}
------------

Participants were randomized at least 2 weeks after index stroke to open‐label SBP targets of 130 to 149 or \<130 mm Hg. Randomization was stratified by clinical center and baseline hypertensive status and had a permuted‐block design with variable block size. Details regarding BP measurement have been published previously.[16](#jah33823-bib-0016){ref-type="ref"}

Outcomes {#jah33823-sec-0016}
--------

Our primary outcome of interest was incidence of rapid kidney function decline, defined as a reduction in eGFR equal to or greater than 30% between the visit before randomization and the visit 1 year afterward. We focused on the first year after randomization because this was the period of medication intensification, as we have published.[5](#jah33823-bib-0005){ref-type="ref"} We also analyzed the mean change in eGFR during the first year of follow‐up as a secondary kidney outcome. Finally, as a secondary outcome of interest, we analyzed the SPS3 primary end point of all stroke to contextualize the risk for rapid kidney function decline with the relative reduction in stroke risk from aggressive BP lowering. This included ischemic stroke, defined as a focal neurological deficit persisting for longer than 24 hours with an absence of hemorrhage, and intracranial hemorrhage, defined by hemorrhage in intracerebral, subdural, epidural, or subarachnoid locations on neuroimaging. Strokes were identified and adjudicated by board‐certified neurologists blinded to assigned SBP target and achieved BP. Other details on outcome adjudication have been published.[16](#jah33823-bib-0016){ref-type="ref"}

Covariates {#jah33823-sec-0017}
----------

Clinical and demographic characteristics were compared at baseline and included in multivariable models. These included age, sex, and race; smoking status, SBP, body mass index, total cholesterol, high‐density lipoprotein cholesterol, self‐reported history of diabetes mellitus or previous lacunar stroke, hypertension, use of statins, use of antihypertensive medications, and, separately, use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Hypertension was defined as an average prerandomization SBP greater than 140 mm Hg or a definite history of hypertension being treated with an antihypertensive.

Statistical Analysis {#jah33823-sec-0018}
--------------------

First, we summarized baseline clinical and demographic characteristics of participants by WMH score tertile. Differences in distribution of categorical variables and means of continuous variables were tested using the chi‐squared and ANOVA tests, respectively.

Next, we estimated the associations of WMH score with baseline kidney function. This was done using unadjusted and multivariable adjusted linear regression.

Then, to evaluate the association of WMHs with 1‐year kidney function decline, we compared incidence of rapid kidney function decline and mean 1‐year kidney eGFR decline in higher versus lower BP arms, stratified by tertile of WMHs. We tested for interaction between BP target and WMH score using logistic regression for the binary outcome of rapid kidney function decline and linear regression for the continuous outcome of 1‐year change in kidney function.

We assessed whether WMH burden modified the effect of intensive BP lowering on recurrent stroke by stratification according to WMH tertile and interaction analyses using Cox proportional hazards models for the SPS3 primary outcome of recurrent stroke.

All analyses were conducted using the Stata (version 14.1; StataCorp LP, College Station, TX) statistical software package. The data, analytical methods, and study materials are available to other researchers upon request for purposes of reproducing the results or replicating the procedure.

Results {#jah33823-sec-0019}
=======

Baseline Characteristics {#jah33823-sec-0020}
------------------------

Among the 2967 participants included in our cross‐sectional and recurrent stroke analyses, mean age was 62.8±10.8 years with a mean eGFR of 80.7±18.7 mL/min/1.73 m^2^ (Table [1](#jah33823-tbl-0001){ref-type="table"}). Distribution of WMH score was right‐skewed, with a median score of 4 (interquartile range, 2--8). Sixty‐three percent of participants were male, 51% were white, 31% had a history diabetes mellitus, and 75% had a history of hypertension. Persons in the highest tertile of WMH were older (mean age, 67.3±10.8 years), were more likely to have hypertension (82%), and had lower eGFR (74.8±18.3). History of previous lacunar stroke (16%) and eGFR \<60 mL/min/1.73 m^2^ (24%) were also most prevalent in the highest WMH tertile. Participants excluded from our cross‐sectional and stroke analyses were more likely to be male, more likely to be white, had lower eGFR, and had a higher proportion of persons with history of lacunar stroke before the presenting stroke compared with included (Table [S1](#jah33823-sup-0001){ref-type="supplementary-material"}). The 566 participants excluded in our analysis of kidney outcomes had a lower SBP, a smaller proportion of Hispanics and former smokers, and a higher proportion of blacks, whites, current smokers, and persons with history of lacunar stroke before the presenting stroke compared with included (Table [S2](#jah33823-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline Clinical and Demographic Characteristics of Secondary Prevention of Small Subcortical Strokes Trial Participants by Tertile of WMH Score

  Characteristic                                                          Lowest Tertile (n=1210)   Middle Tertile (n=937)   Highest Tertile (n=820)   Total (N=2967)                            
  ----------------------------------------------------------------------- ------------------------- ------------------------ ------------------------- ---------------- ------- -------- ------- --------
  Age, y                                                                  59.3                      (10.0)                   63.3                      (10.1)           67.3    (10.8)   62.8    (10.8)
  Male[\*](#jah33823-note-0003){ref-type="fn"}                            785                       (64.9)                   591                       (63.1)           485     (59.1)   1861    (62.7)
  Race[†](#jah33823-note-0004){ref-type="fn"}                                                                                                                                                    
  White                                                                   635                       (52.5)                   483                       (51.5)           386     (47.1)   1504    (50.7)
  Hispanic                                                                373                       (30.8)                   273                       (29.1)           257     (31.3)   903     (30.4)
  Black                                                                   170                       (14.0)                   160                       (17.1)           156     (19.0)   486     (16.4)
  Other                                                                   32                        (2.6)                    21                        (2.2)            21      (2.6)    74      (2.5)
  Smoking                                                                                                                                                                                        
  Never                                                                   506                       (41.8)                   344                       (36.7)           325     (39.6)   1175    (39.6)
  Former                                                                  458                       (37.9)                   384                       (41.0)           343     (41.8)   1185    (39.9)
  Current                                                                 246                       (20.3)                   209                       (22.3)           152     (18.5)   607     (20.5)
  Diabetes mellitus                                                       407                       (33.6)                   330                       (35.2)           252     (30.7)   989     (33.3)
  History of hypertension[†](#jah33823-note-0004){ref-type="fn"}          832                       (68.8)                   716                       (76.4)           676     (82.4)   2224    (75.0)
  Antihypertensive use[†](#jah33823-note-0004){ref-type="fn"}             971                       (80.2)                   802                       (85.6)           739     (90.1)   2512    (84.7)
  ACE inhibitor or ARB use                                                                                                                                                                       
  At baseline[†](#jah33823-note-0004){ref-type="fn"}                      765                       (63.2)                   636                       (67.9)           587     (71.6)   1988    (67.0)
  At 1‐year follow‐up                                                     688                       (67.9)                   569                       (73.9)           504     (75.1)   1761    (71.8)
  Statin use                                                              832                       (68.8)                   662                       (70.7)           549     (67.0)   2043    (68.9)
  Previous lacunar stroke[†](#jah33823-note-0004){ref-type="fn"}                                                                                                                                 
  Yes                                                                     61                        (5.0)                    107                       (11.4)           132     (16.1)   300     (10.1)
  Missing                                                                 2                         (0.2)                    1                         (0.1)            0       (0.0)    3       (0.1)
  Total cholesterol, mg/dL                                                189.8                     (48.3)                   187.1                     (47.1)           185.9   (45.4)   187.9   (47.2)
  High‐density lipoprotein cholesterol, mg/dL                             44.7                      (19.6)                   45.4                      (20.1)           46.6    (14.2)   45.4    (18.5)
  Systolic blood pressure, mm Hg[†](#jah33823-note-0004){ref-type="fn"}   140.1                     (17.3)                   143.2                     (18.9)           147.3   (20.2)   143.0   (18.9)
  Body mass index, kg/m^2^ [†](#jah33823-note-0004){ref-type="fn"}        29.7                      (7.9)                    29.1                      (6.2)            28.1    (5.8)    29.1    (6.9)
  eGFR, mL/min/1.73 m^2^ [†](#jah33823-note-0004){ref-type="fn"}          84.8                      (18.2)                   80.6                      (19.0)           74.8    (18.3)   80.7    (18.9)
  eGFR \<60, mL/min/1.73 m^2^                                             114                       (9.4)                    145                       (15.5)           195     (23.8)   454     (15.3)
  eGFR 60 to 90, mL/min/1.73 m^2^                                         583                       (48.2)                   473                       (50.5)           445     (54.3)   1501    (50.6)
  eGFR \>90, mL/min/1.73 m^2^                                             513                       (42.4)                   319                       (34.0)           180     (22.0)   1012    (34.1)
  WMH score[†](#jah33823-note-0004){ref-type="fn"}                        1.8                       (1.0)                    5.4                       (1.1)            11.0    (2.9)    5.5     (4.1)
  Randomized to systolic blood pressure target \<130 mm Hg                626                       (51.7)                   471                       (50.3)           381     (46.5)   1478    (49.8)

Differences in distribution of categorical variables and means of continuous variables tested using chi‐squared and ANOVA, respectively. Follow‐up data from 2454 participants with baseline WMH score and creatinine measure at 1‐year follow‐up. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; WMH, white matter hyperintensity.

*P* for statistical test \<0.05.

*P*\<0.0005.

WMHs and eGFR at Baseline {#jah33823-sec-0021}
-------------------------

WMH score had a significant inverse association with baseline kidney function. Unadjusted linear regression demonstrated that each point higher in WMH score corresponded to 1.01 (95% CI, 0.85--1.17) mL/min/1.73 m^2^ lower in eGFR, on average. Adjustment for age, sex, and race slightly attenuated the association. After further adjustment for additional traditional chronic kidney disease risk factors and antihypertensive therapy, each point higher in WMH score corresponded to 0.36 (95% CI, 0.18--0.50) mL/min/1.73 m^2^ lower baseline eGFR.

WMHs and Kidney Function Decline After Intensive BP Control {#jah33823-sec-0022}
-----------------------------------------------------------

In the first year after randomization, 100 of the 1236 (8.1%) included participants in the higher‐target arm experienced rapid kidney function decline, compared with 134 of the 1218 (11.0%) in the lower‐target arm (odds ratio=1.40; 95% CI, 1.07--1.84). These findings were similar to those of previous analyses.[5](#jah33823-bib-0005){ref-type="ref"}

The effect of intensive BP lowering on rapid kidney function decline appeared to intensify with increasing WMH score, suggesting an interaction between BP target and WMH score ([Figure](#jah33823-fig-0001){ref-type="fig"}A). Specifically, within the lowest WMH tertile, there were 26% higher odds of rapid kidney function decline in the lower‐target group compared with the higher‐target group, whereas the odds were 34% higher in the lower‐target group compared with the higher‐target group within the middle WMH tertile, and the odds were 71% higher in the lower‐target group compared with the higher‐target group within the highest WMH tertile (Table [2](#jah33823-tbl-0002){ref-type="table"}). A test for interaction, however, did not indicate statistically significant interaction by WMH score (*P*=0.65). Similarly, average kidney function decline in the lower‐target group was 1.49 (95% CI, −0.35 to 3.33) mL/min/1.73 m^2^ faster than in the higher‐target group among persons in the lowest WMH tertile, whereas average decline was 2.17 (95% CI, −0.12 to 4.46) mL/min/1.73 m^2^ faster in the lower‐target group among persons in the middle WMH tertile and 2.56 (95% CI, −0.36 to 4.77) mL/min/1.73 m^2^ faster in the lower‐target group among persons in the highest WMH tertile. A formal test for interaction did not indicate statistically significant interaction by WMH on mean kidney function decline (*P*=0.17).

![Effect of intensive vs usual systolic blood pressure target on rapid eGFR decline and recurrent stroke among persons across the range of brain magnetic resonance imaging WMH scores. Plotted lines depict predicted rates of rapid kidney function decline **(A)** and recurrent stroke **(B)** in higher‐target (solid line) and lower‐target (dashed line) arms. Markers depict observed rates of rapid decline and recurrent stroke in higher target (white squares) and lower‐target (black square) groups within each WMH score. Predictions based on logistic regression (rapid decline) and Cox regression (recurrent stroke) models. eGFR indicates estimated glomerular filtration rate; WMH, white matter hyperintensity.](JAH3-8-e010091-g001){#jah33823-fig-0001}

###### 

Association of Usual Versus Intensive SBP Target With Rapid eGFR Decline in the First Year by WMH Tertile Among 2454 SPS3 Trial Participants

  SBP Target, mm Hg             Events   Odds Ratio   (95% CI)   *P* Value[\*](#jah33823-note-0006){ref-type="fn"}   
  ----------------------------- -------- ------------ ---------- --------------------------------------------------- ------
  Lowest WMH tertile (n=1013)                                                                                        
  130 to 149                    36/498   7.2%         Referent                                                       
  \<130                         46/515   9.0%         1.26       (0.80--1.98)                                        0.32
  Medium WMH tertile (n=770)                                                                                         
  130 to 149                    33/381   8.7%         Referent                                                       
  \<130                         44/389   11.3%        1.34       (0.84--2.16)                                        0.22
  Highest WMH tertile (n=671)                                                                                        
  130 to 149                    31/357   8.7%         Referent                                                       
  \<130                         44/314   14.0%        1.71       (1.05--2.80)                                        0.03

*P* for interaction=0.65. eGFR indicates estimated glomerular filtration rate; SBP, systolic blood pressure; SPS3, Secondary Prevention of Small Subcortical Strokes; WMH, white matter hyperintensity.

*P* value for OR within WMH tertile.

WMHs and Stroke After Intensive BP Control {#jah33823-sec-0023}
------------------------------------------

Overall incidence of recurrent stroke was 7.9% in the lower‐target arm and 9.6% in the higher‐target arm (hazard ratio=0.80; 95% CI, 0.63--1.03). These findings were similar to those in past analyses.[2](#jah33823-bib-0002){ref-type="ref"} Persons in the highest WMH tertile had the highest overall stroke incidence (12.3%), but they also had the largest absolute reduction in stroke incidence from intensive BP lowering (3.4%; Table [3](#jah33823-tbl-0003){ref-type="table"}). Within the lowest WMH tertile, the hazard ratio for stroke recurrence in the lower BP target arm compared with the higher‐target arm was 1.13 (95% CI, 0.73--1.75) compared with a hazard ratio of 0.73 (95% CI, 0.49--1.09) within the highest WMH tertile. Kaplan--Meier plots of stroke within tertiles of WMH score are depicted in Figure [S1](#jah33823-sup-0001){ref-type="supplementary-material"}. A test for interaction indicated significant interaction between WMH score and the intensive BP intervention for the outcome of stroke (*P*=0.04), that is, intensive BP lowering provided greater stroke prevention in those with higher WMH burden ([Figure](#jah33823-fig-0001){ref-type="fig"}B).

###### 

Effect of Intensive Blood Pressure Lowering on Recurrent Stroke, Stratified by WMH Score in 2967 Participants of Secondary Prevention of Small Subcortical Strokes Trial

  Systolic Blood Pressure Target, mm Hg   Events   Hazard Ratio   (95% CI)   *P* Value[\*](#jah33823-note-0008){ref-type="fn"}   
  --------------------------------------- -------- -------------- ---------- --------------------------------------------------- -------
  Lowest WMH tertile (n=1210)                                                                                                    
  130 to 149                              37/584   6.3%           Referent                                                       
  \<130                                   44/626   7.0%           1.13       (0.73--1.75)                                        0.589
  Medium WMH tertile (n=937)                                                                                                     
  130 to 149                              45/466   9.7%           Referent                                                       
  \<130                                   32/471   6.8%           0.67       (0.43--1.06)                                        0.089
  Highest WMH tertile (n=820)                                                                                                    
  130 to 149                              61/439   13.9%          Referent                                                       
  \<130                                   40/381   10.5%          0.73       (0.49--1.09)                                        0.123

Included participants analyzed based on intention to treat. Median follow‐up durations in the lowest, medium, and highest WMH tertiles were 3.7, 3.3, and 3.4 years, respectively. *P* for interaction=0.04. WMH indicates white matter hyperintensity.

*P* value for hazard ratio within WMH tertile.

Discussion {#jah33823-sec-0024}
==========

In our secondary analyses of the SPS3 trial, we found that higher white matter disease burden was independently associated with lower baseline eGFR. We also found that degree of WMH burden, a marker of cerebral small vessel disease, may identify persons at highest risk for rapid kidney function decline from intensive BP lowering; however, this interaction was not statistically significant. Additionally, we observed that a higher WMH score distinguished persons who derive the highest benefit from aggressive BP lowering to reduce risk for recurrent stroke. Our findings suggest that WMH, a marker of microvascular disease in the brain, may identify subgroups of persons with different benefits and risk from intensive BP lowering. Specifically, although persons with a higher burden of microvascular disease may be at higher risk for rapid kidney function decline from aggressive BP lowering, they also appear most likely to benefit in secondary stroke prevention.

This study supports previous literature describing an independent association between cerebrovascular disease and lower kidney function levels.[14](#jah33823-bib-0014){ref-type="ref"} In our study, this association was demonstrated to be independent of age, sex, race, and other vascular risk factors. This study also contributes to a much smaller body of literature investigating the relationship between cerebrovascular disease and change in kidney function over time, here, in the context of BP lowering.[21](#jah33823-bib-0021){ref-type="ref"}, [22](#jah33823-bib-0022){ref-type="ref"}

We and others have shown that intensive BP lowering results in increased risk for rapid kidney function decline compared with higher BP target.[3](#jah33823-bib-0003){ref-type="ref"}, [4](#jah33823-bib-0004){ref-type="ref"}, [5](#jah33823-bib-0005){ref-type="ref"} Our study extends these findings by showing that WMHs, a marker of cerebral small‐vessel disease, may identify persons most likely to have creatinine elevation with intensive BP lowering. To our knowledge, this is 1 of very few studies to investigate the effectiveness of intensive BP lowering for prevention of stroke within subgroups defined by level of white matter disease in the brain.[11](#jah33823-bib-0011){ref-type="ref"}, [23](#jah33823-bib-0023){ref-type="ref"} Several previous studies have demonstrated an elevated risk of incident and recurrent stroke in those with higher levels of white matter disease.[10](#jah33823-bib-0010){ref-type="ref"} Our analysis showed those with higher levels of white matter disease may have a greater reduction in stroke recurrence from intensive BP lowering. The larger absolute benefit may be explained by this population\'s higher absolute risk.

Taken together, our findings could be explained by a common mechanism, such as impaired small‐vessel autoregulation in the brain and kidney among persons with higher burden of WMH. Both the brain and kidney are perfused by low‐resistance vascular beds with small vessels that rely on strict autoregulation to manage hemodynamic stress from large supplying arteries.[15](#jah33823-bib-0015){ref-type="ref"}, [24](#jah33823-bib-0024){ref-type="ref"} It is plausible that WMHs identify a vascular phenotype with less autoregulatory reserve to manage long‐term hemodynamic stress, whether it is from hypertension or intensive BP lowering.

Alternatively, the findings of greater stroke prevention and possibly greater increase in kidney function decline could be explained by the effects of renin‐angiotensin system blockade in the kidney and cerebral vasculature. Participants in higher WMH tertiles of our study had more‐prevalent use of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers at baseline and 1‐year follow‐up (Table [1](#jah33823-tbl-0001){ref-type="table"}). We have previously shown that angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers were commonly added to achieve BP targets in SPS3.[5](#jah33823-bib-0005){ref-type="ref"} Excessive renin‐angiotensin system pathway blockade has been shown to be harmful to kidney function in previous trials.[25](#jah33823-bib-0025){ref-type="ref"}, [26](#jah33823-bib-0026){ref-type="ref"} On the other hand, renin‐angiotensin system blockade has also been shown to have protective effects in cerebral tissue during ischemic injury.[27](#jah33823-bib-0027){ref-type="ref"}, [28](#jah33823-bib-0028){ref-type="ref"} This could explain greater stroke prevention from intensive BP lowering at the expense of kidney function in our population of nonproteinuric persons with elevated stroke risk.

We do not believe that our findings can be attributed to the association between higher WMH burden and lower eGFR, because we have previously reported that the effect of a lower BP target increasing eGFR decline is more pronounced at higher baseline eGFR levels.[5](#jah33823-bib-0005){ref-type="ref"} This makes it unlikely that participants with higher WMH burden had more kidney function decline from intensive BP lowering because of their baseline eGFR, which we found in this study to be lower.

The clinical significance of rapid kidney function decline in the context of intensive BP lowering remains uncertain. Our previous work showed no association of rapid eGFR function decline with adverse outcomes in the setting of intensive BP lowering.[5](#jah33823-bib-0005){ref-type="ref"} It has also been demonstrated that intensive BP lowering was not associated with higher levels of tubular kidney injury markers in a primary prevention trial of intensive BP lowering, even among those with increases in serum creatinine.[8](#jah33823-bib-0008){ref-type="ref"}, [29](#jah33823-bib-0029){ref-type="ref"} This suggests that rapid kidney function decline after intensive BP lowering may primarily represent a hemodynamic effect. It has also been demonstrated that most acute kidney injury in a trial of intensive BP lowering is mild and reversible.[30](#jah33823-bib-0030){ref-type="ref"} Nevertheless, we believe this outcome is important because rapid kidney function decline may cause clinicians to withdraw potentially beneficial antihypertensive therapy.

The randomized‐controlled design of SPS3 is a key strength of this study, which facilitated investigation into the benefit and harm of intensive BP control. Investigating WMH as a predictor of kidney function decline is novel. It is also very generalizable to the clinical assessment of stroke patients and their prognosis. Additionally, our longitudinal outcome of kidney function decline offers more‐dynamic information about the relationship between cerebrovascular disease and kidney function than is available from previously utilized cross‐sectional analyses. Our outcome of 1‐year kidney function decline may have been too soon after enrollment to observe statistically significant interactions between WMHs and intensive BP lowering with respect to kidney function decline. Additionally, the exclusion of 566 participants in our longitudinal analysis introduces the possibility of bias that could also have affected our results. Despite these limitations and the lack of statistical significance in some of our results, we believe these results of our analyses serve well to generate hypotheses about shared mechanisms of brain and kidney vascular injury.

Future research should be directed at further determining the significance of cerebrovascular disease regarding renal and cardiovascular outcomes. Other identifiable features of small‐vessel cerebrovascular disease, including silent brain infarcts or cerebral microbleeds, may prove to be useful predictors of renal and cardiovascular outcomes. With longer follow‐up than available in the present study, the association of white matter hyperintensities and other markers of small‐vessel disease in the brain with long‐term kidney function decline could also be further elucidated. In addition, studying the effect of intensive BP lowering in a population with proteinuria may offer additional insight toward its relative benefit and harm in the context of different cardiovascular risk profiles.

In summary, higher WMH burden was associated with lower baseline eGFR, which supports the notion of shared vascular injury mechanisms. Burden of WMHs might be able identify persons at increased risk of rapid kidney function decline from intensive BP lowering, though this interaction was not statistically significant. Interestingly, those with high WMH burden were also most likely to benefit from intensive BP lowering to prevent stroke recurrence. Larger studies are required to replicate these findings.
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